[ad_1]
The National Agency for Sanitary Surveillance (Anvisa) approved the registration of a new cure for the treatment of cystic fibrosis, a genetic disease still incurable that causes an accumulation mucus in the lungs, resulting in inflammation and infections can cause respiratory failure.
According to the Orkambi leaflet (lumacaftor + ivacaftor), the use of the drug results in a rapid and prolonged improvement in lung function, thereby reducing the patient's hospitalization. Another positive effect of the cure, according to Anvisa, is the improvement of nutritional assessments of those who undergo treatment.
+ An 8-year-old boy with a brain pierced by a barbecue skewer at BA
Orkambi will be available as a tablet in concentrations of 100 mg + 125 mg and 200 mg + 125 mg. The drug is indicated for patients over 6 years of age and adults for the treatment of cystic fibrosis.
Always be the first to know. Download
[ad_2]
Source link
